Shifting Dietary Trends Driven by GLP-1 Inhibitors

The rise of GLP-1 inhibitors, including popular medications like Ozempic, is significantly altering dietary preferences globally. These drugs, originally designed to manage diabetes, have demonstrated the ability to reduce appetite and lead to a caloric intake reduction of nearly 800 kilocalories per day—about a 20% decrease. As a result, many consumers are opting for leaner protein sources, steering clear of high-fat meats and processed foods.

Implications for the Livestock Industry

Aidan Connolly, president of AgriTech Capital LLC, underlines the challenges this shift poses for the livestock feed and additives industry. With approximately 15.5 million adults in the United States currently using GLP-1 medications, the demand dynamics for meat and protein sources are evolving.

Consumer Preferences Change

As health-conscious choices become increasingly prevalent, lean proteins such as poultry and fish are gaining traction among consumers. This trend highlights a fundamental shift in dining habits, reflecting a broader preference for nutritious, lower-calorie food options in place of traditional high-calorie fare.

Get full access to all stories on Poultry World

This Premium article is exclusively available for subscribers

Obtain insights from exclusive interviews

Dive into articles covering trending industry topics

Get a glimpse into poultry farms worldwide

All the news is brought to you by experienced editors and experts from around the world

Nathalie
Kinsley

Fabian
Brockötter

Tony
McDougal